Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

Replicate Supramolecular Self-Replicating Antimicrobials

Coordinator
Universidad De Santiago De Compostela, Spain
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101163359

What the project is doing

In the project's own words, from its summary on CORDIS.

This project aims to address the urgent need for new antimicrobial agents by developing a conceptually new strategy to damage bacterial membranes with supramolecular fibres. Dormant (non-assembling) precursors will accumulate in the membrane of bacteria for in situ switch-on of self-assembly and membrane lysis. Specific metabolic routes of bacteria, absent in mammalian cells, will be used to transport supramolecular precursors into the membrane of bacteria with full cell specificity.

Once in the membrane, precursors will combine to generate self-assembling peptide amphiphiles (PAs). Importantly, once formed, the supramolecular assemblies can catalyse their own synthesis in bacterial membranes, causing a dramatic acceleration in PA production and antimicrobial fibrillation. This unprecedented antimicrobial design borrows concepts from cooperative self-assembly, supramolecular autocatalysis and rational peptide design, leading to a self-amplified therapeutic action.

This will be the first self-replicating antimicrobial that can make copies of itself to boost membrane damage once activated in target pathogens. Co-assembly of PAs and their precursors will create catalytic microenvironments by templation of reactive building blocks. Overall, this project will lay down structural and mechanistic determinants for biological membrane interfacing with targeted and self-replicating supramolecular nanomaterials.

In a broader picture, the REPLICATE technology aims to spark a re-conceptualisation of drug design by drawing the attention to supramolecular therapeutics, which may open new exciting opportunities in biomedicine not accessible from traditional single-molecule drugs.

Topics

Who is involved

OrganisationCityCountryRole
Universidad De Santiago De CompostelaSantiago De CompostelaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI